Navigation Links
Directly observed HIV treatment by patient-nominated treatment supporter improves survival
Date:6/11/2010

When applied to HIV care, the community-based model of directly observed therapy (DOT) has no effect on virologic outcomes, but significantly improves patient survival. This is according to researchers at the Johns Hopkins Bloomberg School of Public Health, in collaboration with colleagues at University of Cape Town, South Africa, who conducted the first randomized controlled trial of patient-nominated treatment-supporters providing partial DOT in resource-limited settings. The researchers found that mortality rates were lower among DOT patients than among self-monitored antiretroviral therapy (ART). The results are featured in the June 1, 2010, issue of AIDS.

Directly observed therapy (DOT) is a treatment strategy commonly used in tuberculosis control programs, in which a health care worker ensures that medication is taken by patients at health care facilities. Previous observational studies suggested the effectiveness of community health supporters (friends or family members) performing DOT antiretroviral therapy as a strategy to improve adherence, but data from randomized trials were previously lacking.

"Community DOT-ART showed no effect on virologic outcomes, but was associated with greater CD4 cell count increases at 6-month follow up," said Jean B. Nachega, MD, PhD, MPH, lead author of the study, associate scientist in the Bloomberg School's Department of International Health. Nachega is also, professor of medicine and director of the Center for Infectious disease at Stellenbosch University, Cape Town, South Africa.) "More importantly, there were 20 deaths in the control group compared to 9 deaths among those who received the intervention, and mortality was independently associated with the study arm in multivariate Cox regression analyses. This survival benefit was not fully explained by improved adherence, virologic or immunologic outcomes."

For the study, researchers analyzed data from 274 adult patients initiating antiretroviral therapy (ART) at a public HIV clinic in Cape Town, South Africa. Patients were randomized to treatment-supporter DOT-ART or self -administered ART. In the DOT group, patients selected someone from their own personal network such as a family member or friend to observe at least one medication dose every day and provide support. DOT-ART patients and supporters received baseline and follow-up training and monitoring. Researchers defined the primary endpoints as the number of patients with undetectable HIV viral loads (fewer than 400 copies/ml) and a mean change in CD4 cell counts at 6, 18, 12 and 24 months. Secondary endpoints were pill count adherence, new or recurrent AIDS defining illness and all-cause mortality.

"The `social capital provided by a trusted patient-nominated treatment supporter (e.g. material and emotional support, health care utilization, etc.), may have contributed to save lives, regardless of the DOT component of our intervention" said Nachega. "Moving forward, there is a critical need to identify and assess additional community-based interventions to improve outcomes of HIV patients worldwide. We recommend these community-based DOT-ART interventions be large enough to detect meaningful clinical and public health differences that improve patients' conditions and save lives. In addition, they should target patients with documented poor adherence and collect both qualitative and quantitative outcomes."


'/>"/>

Contact: Natalie Wood-Wright
nwoodwri@jhsph.edu
410-614-6029
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Related medicine news :

1. Survival in metastatic breast cancer directly linked to circulating tumor cells
2. Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How
3. Findatopdoc.com Uses Cutting Edge Technology in Bringing the Leading Physicians of the World Directly to Your Computer For Consumers to Find a Top Doctor
4. Racial disparity observed in varus and valgus thrust study of knee OA
5. Fewer left-sided colorectal tumors observed after colonoscopies
6. Study shows Hodgkin lymphoma survivors lack post-treatment screening for other cancers
7. 5th ESU Master Class on Medical Treatment for Urological Cancer
8. Research: Major breakthrough will revolutionize the screening and treatment of genetic diseases
9. Knowledge translation keeps treatment current
10. Consortium seeks best treatment for HIV-positive cancer patients
11. New treatment regimen shown effective against advanced ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... in unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as ... premier society for this important science. , The Teratology Society ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, ... strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable ... management of complex spine deformity cases, particularly in children. , GSO’s focus is ...
(Date:4/24/2017)... ... , ... The Santana Telehealth Project was honored with the 2017 ATA Humanitarian ... Association’s annual conference, on April 23 in Orlando, FL. , “I am proud that ... of the poor and underserved in other parts of the world,” said Jonathan Linkous, ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, ... inhabiting the rarified air of pop and film stardom.(1) Not to be left out ... the smile. Grins now run the gamut from being encrusted with jewels and precious ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology: